Labiotech.eu

axovant parkinsons disease neuron dopamine

News and Trends 25 Oct 2018

Parkinson’s Disease Gene Therapy Clinical Trial Launched in UK

A gene therapy for Parkinson’s disease developed by Swiss biotech Axovant has been used on the first patient in a Phase I/II trial at University College London. Parkinson’s disease is a neurodegenerative disease, caused by a lack of the neurochemical dopamine in regions of the brain handling motor functions causing debilitating symptoms such as rigidity […]

October 25, 2018 - 2 minutesmins - By Jonathan Smith

Interview 25 Oct 2018

Mastering the Competitive World of Immuno-oncology

In recent years the oncology world has focused on using the immune system to target cancer, with CAR-T cell therapy and other success stories revolutionizing the field. Ulf Grawunder, CEO and founder of NBE Therapeutics, a company using antibody drug conjugates to target cancer, discussed how to navigate the competitive area of immuno-oncology at our […]

October 25, 2018 - 5 minutesmins - By Helen Albert

News and Trends 24 Oct 2018

UK Microbiome Company Gets Financial Boost for Live Bacterial Therapy

UK-based Microbiotica has received a £4M investment from Seventure’s fund dedicated to investments in the microbiome space. With Seventure coming on board as a new investor, Microbiotica has now raised a total of £12M since its foundation in 2016. The company, a spin-out of the Sanger Institute in Cambridge, seeks to find and exploit precise […]

October 24, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Oct 2018

15-Minute Cardiovascular Blood Test to Sell Across Europe

French diagnostics company Magnisense has raised €5M to expand the sales of its emergency tests for heart attack and heart failure, which can be performed at home in just 15 minutes. The diagnostic technology developed by Magnisense, called MiAG, uses magnetic nanoparticles to detect extremely low quantities of cardiovascular biomarkers in the blood. “MiAG allows […]

October 24, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Oct 2018

Microbiome Biotech Enterome Signs Deal With Takeda Worth up to €600M

The French biotech Enterome and Takeda are teaming up to fight Crohn’s disease, with a deal worth up to €600M. The two companies will collaborate in the development and commercialization of Enterome’s lead microbiome-targeting treatment currently in Phase I trials. Under the terms of the deal, Takeda will pay Enterome €44M upfront, and up to […]

October 23, 2018 - 2 minutesmins - By Jonathan Smith

Interview 23 Oct 2018

Bridging the Academia-Industry Divide: Lessons from a Serial Biotech Entrepreneur

What does it take to be a successful biotech entrepreneur? I put this and other similar questions to Dinko Valerio, a highly experienced Dutch geneticist turned serial entrepreneur and investor. While there are many great scientists, it takes a certain something to be able to cross over into industry and build a profitable business. Dinko […]

October 23, 2018 - 8 minutesmins - By Helen Albert

Innate Pharma Cancer immunotherapy header

News and Trends 22 Oct 2018

Innate’s Cancer Immunotherapy Combo Beats Standard Treatment Twofold

A combination cancer immunotherapy from French biotech Innate Pharma was twice as effective at treating recurrent squamous cell carcinoma as standard therapy in a Phase II trial. Squamous cell carcinoma is a head and neck cancer that forms lesions in the mucous membranes of body cavities such as the mouth, nose and throat. “Patients are […]

October 22, 2018 - 2 minutesmins - By Jonathan Smith

Aelix Therapeutics Gilead Functional HIV Cure

News and Trends 19 Oct 2018

Spanish Biotech Partners Gilead to Develop Functional HIV Cure

AELIX Therapeutics and Gilead will run a clinical trial testing a combination of treatments that has potential to let HIV-infected people ditch lifelong therapy. The trial, which will run in Spain, is planned to start in early 2019 and will recruit around 90 patients in the early stages of HIV infection. After receiving the […]

October 19, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

BOTW silk biomaterials nerve repair lomazzo

Startup Scout 19 Oct 2018

This Biotech Spins Silk That Can Repair Nerves

We fly to Lomazzo, Italy, this week to visit Silk Biomaterials. As the name implies, the company is testing different medical applications of silk, such as in nerve repair. Mission: Founded in 2014, Silk Biomaterials uses silk as a scaffold material for medical applications such as vascular grafts and peripheral nerve repair. In many tissue […]

October 19, 2018 - 4 minutesmins - By Jonathan Smith

More News! 18 Oct 2018

Phase III Triumph for Topical Hormonal Acne Treatment

The Italian biotech Cassiopea reports good news for acne sufferers. Its hormonal anti-acne treatment Winlevi significantly helped to reduce acne in two Phase III trials. Winlevi, when applied to the skin, cleared the acne in more than twice as many participants with moderate or severe acne as placebo. The treatment also showed good safety results […]

October 18, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 17 Oct 2018

Belgian Firm Will Develop Antibiotic Alternatives for Industrial Biotech Using CRISPR

Syngulon will be developing antibacterial peptides using CRISPR/Cas9 gene editing technology thanks to an agreement with ERS Genomics, which licenses out CRISPR intellectual property in the EU. CRISPR technology is a hot topic in the biotech industry because it makes gene editing faster and easier than other techniques. This could make it very useful in […]

October 17, 2018 - 2 minutesmins - By Jonathan Smith

More News! 17 Oct 2018

The EU Patent of the Best Selling Drug Has Expired, What Does it Mean for Biotech?

AbbVie’s Humira, a treatment for inflammatory disease and the world’s best-selling drug, is no longer patent-protected in the EU. Competitors are already taking advantage of it. Humira is an antibody drug, called adalimumab, that has been topping the lists of best-selling drugs for years. Last year alone, it made over €15B in sales worldwide. The […]

October 17, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Parkinson’s Disease Gene Therapy Clinical Trial Launched in UK

Mastering the Competitive World of Immuno-oncology

UK Microbiome Company Gets Financial Boost for Live Bacterial Therapy

15-Minute Cardiovascular Blood Test to Sell Across Europe

Microbiome Biotech Enterome Signs Deal With Takeda Worth up to €600M

Bridging the Academia-Industry Divide: Lessons from a Serial Biotech Entrepreneur

Innate’s Cancer Immunotherapy Combo Beats Standard Treatment Twofold

Spanish Biotech Partners Gilead to Develop Functional HIV Cure

This Biotech Spins Silk That Can Repair Nerves

Phase III Triumph for Topical Hormonal Acne Treatment

Belgian Firm Will Develop Antibiotic Alternatives for Industrial Biotech Using CRISPR

The EU Patent of the Best Selling Drug Has Expired, What Does it Mean for Biotech?

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!